Дата выпуска | Название | Автор(ы) |
2023 | Development of quantification methods of a new selective carbonic anhydrase II inhibitor in plasma and blood and study of the pharmacokinetics of its ophthalmic suspension in rats | Khokhlov, A. L.; Yaichkov, I. I.; Korsakov, M. K.; Shetnev, A. A.; Volkhin, N. N. |
2024 | Ethical aspects of clinical trials in Russia and BRICS countries: An overview | Simeniv, S. Y.; Khokhlov, A. L.; Soldatova, O. N.; Pyatigorskaya, N. V. |
2024 | Identification and synthesis of metabolites of 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide | Khokhlov, A. L.; Yaichkov, I. I.; Shetnev, A. A.; Panova, V. A.; Efimova, Yu. A. |
2024 | Identification and synthesis of metabolites of the new 4.5-dihydroisoxazol-5-carboxamide derivate | Khokhlov, A. L.; Yaichkov, I. I.; Alexeev, M. A.; Korsakov, M. K.; Shetnev, A. A. |
2024 | Identification and synthesis of metabolites of the new antiglaucoma drug | Khokhlov, A. L.; Yaichkov, I. I.; Korsakov, M. K.; Shetnev, A. A.; Ivanovskiy, S. A. |
2018 | Methodical approaches to bioassay of substances containing unstable functional groups | Khokhlov, A. L.; Yaichkov, I. I.; Dzhurko, Yu. A.; Shitov, L. N.; Shitova, A. A. |
2020 | Review of bioequivalence studies of cholecalciferol drugs | Khokhlov, A. L.; Romodanovsky, D. P. |
2020 | Risk management strategy for preventing the reduced treatment effectiveness from the position of drug interactions and polypharmacy in patients with coronary heart disease | Gruzdeva, A. A.; Khokhlov, A. L.; Ilyin, M. V. |
2024 | The evaluation of pharmacokinetic parameters of 4-(5-methyl-1,3,4-oxadiazole-2-yl)- benzenesulfonamide and its metabolites in rat plasma | Khokhlov, A. L.; Yaichkov, I. I.; Shetnev, A. A.; Korsakov, M. K.; Volkhin, N. N. |